Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
September 24, 2021
Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.
- Targets
- Arbor Pharmaceuticals, Inc.
- Sellers
- JW Asset Management, KKR
- Industry
- Pharmaceuticals
- Location
- Georgia, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Collegium Pharmaceutical Completes Acquisition of AZSTARYS from Corium Therapeutics
May 12, 2026
Healthcare Services
Collegium Pharmaceutical, Inc. completed its acquisition of AZSTARYS, a prescription CNS stimulant for ADHD, from Corium Therapeutics. The deal is valued at approximately $650 million in cash, with additional milestone-based consideration of up to $135 million.
-
Azurity Pharmaceuticals Acquires Covis Pharma
March 14, 2025
Pharmaceuticals
Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.
-
Azurity Pharmaceuticals Acquires Slayback Pharma
September 27, 2023
Pharmaceuticals
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
PharmaLex Acquires Arbour Group from Keystone Capital
February 12, 2020
Healthcare Services
The PharmaLex Group has acquired Arbour Group, LLC from Keystone Capital. The acquisition expands PharmaLex’s regulatory compliance, quality management and connected health capabilities and strengthens its presence in the United States.
-
CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals
June 12, 2019
Pharmaceuticals
CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.